Cue Biopharma Inc Stock Price, News & Analysis

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock shares and accompanying warrants. The offering includes the option for pre-funded warrants to purchase common stock. Oppenheimer & Co is acting as the sole book-running manager, with Newbridge Securities as co-manager.

The offering is subject to market conditions, and details regarding size and terms are not yet finalized. A shelf registration statement for this offering has been filed with the SEC and declared effective. The company will make the offering available through a prospectus supplement and accompanying prospectus.

Cue Biopharma (Nasdaq: CUE) has appointed Lucinda Warren as Chief Business Officer (CBO). With over 30 years of experience in the pharmaceutical and biotechnology sectors, Warren brings extensive expertise in strategic transactions, portfolio optimization, and alliance management. Her appointment follows Cue Biopharma's recent business restructuring and autoimmune program prioritization.

Warren's role will be important in advancing the company's core corporate objectives, particularly in aligning with third-party partnerships and collaborations to develop their platform of potential breakthrough immunotherapies. Her background includes significant roles at Johnson & Johnson and Janssen, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management.

Cue Biopharma (Nasdaq: CUE) is set to present at The Promise of Interleukin-2 Therapy Conference in Paris, France, from September 4-7, 2024. Two key presentations are scheduled:

1. On September 6, Dr. Steven Quayle will present preclinical data on CUE-401, a novel bispecific fusion protein that induces and expands regulatory T cells through co-delivery of IL-2 and TGF-β.

2. On September 7, Dr. Matteo Levisetti will discuss the clinical safety and efficacy of the company's lead oncology programs CUE-101 and CUE-102, which selectively target IL-2 to tumor-specific T cells for enhanced efficacy and safety profiles.

These presentations highlight Cue Biopharma's innovative approach in developing therapeutic biologics to modulate disease-specific T cells.

Cue Biopharma (Nasdaq: CUE) reported Q2 2024 financial results and recent business highlights. Key points include:

1. CUE-101 showed promising results in HPV+ R/M HNSCC, with 46% ORR in 1L therapy and 20.8 months mOS in 2L+ monotherapy.

2. CUE-102 demonstrated dose-dependent T cell activation and anti-tumor activity in refractory metastatic cancers.

3. Q2 2024 collaboration revenue increased to $2.7 million from $1.4 million in Q2 2023.

4. R&D expenses decreased to $9.5 million in Q2 2024 from $10.7 million in Q2 2023.

5. Cash and cash equivalents were $30.0 million as of June 30, 2024, expected to fund operations through Q2 2025.

Cue Biopharma (Nasdaq: CUE) has announced a conference call and webcast scheduled for August 19, 2024, at 4:30 p.m. EDT to provide a business update. The company will discuss its recent restructuring and strategic prioritization, focusing on enhancing near-term shareholder value by:

• Refocusing resources on autoimmune programs CUE-401 and CUE-501
• Allowing data from ongoing oncology trials for CUE-101 and CUE-102 to mature

The call will also cover clinical and business updates, market opportunities, and anticipated near-term milestones. Investors can access the call via phone or webcast, with options for both domestic and international participants.

Cue Biopharma (Nasdaq: CUE) has announced a strategic shift to prioritize its autoimmune programs, aiming to focus on near-term and intermediate value creation. The company will retain its oncology programs as clinical data continues to mature. This restructuring is expected to reduce annualized capital and workforce requirements by approximately 25%.

Key points:

• Focus on autoimmune programs CUE-401 and CUE-501
• Retention of oncology programs CUE-101 and CUE-102
• Projected annual cash burn reduction to approximately $30 million
• Workforce reduction of about 25% across various departments
• Cash runway expected to extend into mid-year 2025

Cue Biopharma has presented updated data from its Phase 1 trial of CUE-101 at the 2024 ASCO Annual Meeting, revealing promising results for HPV+ head and neck cancer. The combination of CUE-101 and pembrolizumab in first-line (1L) treatment showed a 46% overall response rate (ORR) and a 96% 12-month overall survival (OS). For second-line (2L) and beyond, median overall survival (mOS) was 20.8 months with CUE-101 monotherapy, significantly higher than historical comparisons. No significant safety concerns emerged. Additionally, early data from CUE-102 indicated positive immune response and tolerability.

Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in two significant investor healthcare conferences this June 2024. The company, listed on Nasdaq with the ticker CUE, focuses on developing therapeutic biologics targeting disease-specific T cells.

On June 6, Cue Biopharma will present at the Jefferies Global Healthcare Conference in New York, discussing its progress in oncology and autoimmune platforms. The presentation by Anish Suri, Ph.D., President and Chief Scientific Officer, will be available via webcast.

On June 24, the company will participate in the Oppenheimer Novel Targets and Immunology Summit, also in New York. Dr. Suri will join a panel to discuss repurposing cancer targets for immunology. These events will provide updates on clinical and preclinical advancements and strategic approaches.

Cue Biopharma, Inc. reported their first-quarter 2024 financial results, showcasing an increase in collaboration revenue to $1.7 million due to partnerships. They highlighted advancements in clinical trials for CUE-101 and CUE-102, as well as the expansion of their pipeline to include programs for autoimmune and inflammatory diseases. The company emphasized progress in their autoimmune program, CUE-401, with Ono Pharmaceutical, and the development of the bispecific Immuno-STAT CUE-500 series. Financially, Cue Biopharma reported $41.0 million in cash and cash equivalents as of March 31, 2024, with expectations to fund operations into the first quarter of 2025.